医学
荟萃分析
内科学
相对风险
益生菌
不利影响
置信区间
腹泻
临床试验
科学网
2019年冠状病毒病(COVID-19)
随机对照试验
疾病
生物
细菌
传染病(医学专业)
遗传学
作者
Suelen Neris Almeida Viana,Tamires do Reis Santos Pereira,Janaína de Carvalho Alves,Caroline Tianeze de Castro,Lucas Santana C da Silva,Lúcio Henrique Sousa Pinheiro,Mariana Nougalli Roselino
标识
DOI:10.1080/10408398.2022.2128713
摘要
SARS-CoV-2 is the virus that causes the new global pandemic, which has already resulted in millions of deaths, affecting the world's health and economy. Probiotics have shown benefits in a variety of diseases, including respiratory infections, and may be beneficial in the adjunctive treatment of COVID-19. This study analyzed the effectiveness of probiotics as adjunctive treatment in reducing symptoms of patients with COVID-19, through a systematic review with meta-analysis. The EMBASE (Elsevier), Pubmed, Scopus, Web of Science and International Clinical Trials Registry Platform (ICTRP) were searched through March 16, 2022. The risk ratio (RR) with 95% confidence intervals (CIs) was estimated using a fixed-effect model. RoB 2 and ROBINS I were used to assess the risk of bias of the included studies. Nine studies were included (7 clinical trials and 2 cohorts), of which three clinical trials comprised the meta-analysis. Results showed that probiotics were associated with a significant 51% reduction in symptoms reported by COVID-19 patients (RR 0.49, 95% CI 0.40-0.61). There was a significant improvement in cough (RR 0.56, 95% CI 0.37-0.83), headaches (RR 0.17, 95% CI 0.05-0.65), and diarrhea (RR 0. 33, 95% CI 0.12-0.96) of patients on probiotic therapy. These findings suggest that probiotic supplementation is effective in improving symptoms of COVID-19.
科研通智能强力驱动
Strongly Powered by AbleSci AI